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Objective. To assess the clinical value of 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in a prospective cohort of patients with large vessel vasculitis (LVV) and comparator subjects.
Methods. Patients with Takayasu arteritis and giant cell arteritis were studied, along with a comparator group consisting of patients with hyperlipidemia, patients with diseases that mimic LVV, and healthy controls. Participants underwent clinical evaluation and FDG-PET imaging, and patients with LVV underwent serial imaging at 6-month intervals. We calculated sensitivity and specificity of FDG-PET interpretation for distinguishing patients with clinically active LVV from comparator subjects and from patients with disease in clinical remission. A qualitative summary score based on global arterial FDG uptake, the PET Vascular Activity Score (PETVAS), was used to study associations between activity on PET scan and clinical characteristics and to predict relapse.
Results. A total of 170 FDG-PET scans were performed in 115 participants (56 patients with LVV and 59 comparator subjects). FDG-PET distinguished patients with clinically active LVV from comparator subjects with a sensitivity of 85% (95% confidence interval [95% CI] 69, 94) and a specificity of 83% (95% CI 71, 91). FDG-PET scans were interpreted as active vasculitis in most patients with LVV in clinical remission (41 of 71 [58%]). Clinical disease activity status, disease duration, body mass index, and glucocorticoid use were independently associated with activity on PET scan. Among patients who underwent PET during clinical remission, future clinical relapse was more common in patients with a high PETVAS than in those with a low PETVAS (55% versus 11%; P =0.03) over a median follow-up period of 15 months.
Conclusion. FDG-PET provides information about vascular inflammation that is complementary to, and distinct from, clinical assessment in LVV. FDG-PET scan activity during clinical remission was associated with future clinical relapse.
Positron emission tomography (PET) to detect regional distribution of 18 F-fluorodeoxyglucose (FDG) is an established form of molecular imaging currently used to detect/diagnose disease and monitor treatment response in oncologic diseases (1) . Activated inflammatory cells, including macrophages, exhibit increased glycolytic activity and thus accumulate FDG in a manner similar to certain tumor cells, making FDG-PET a potentially useful modality to assess the extent of inflammation in tissue (2) . However, the use of FDG-PET to diagnose and monitor inflammatory diseases remains a subject of controversy (3) .
Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are the 2 major forms of large vessel vasculitis (LVV), defined by inflammation of the aorta and primary branches (4) . Clinical assessment of disease activity in LVV can be challenging, thus posing a barrier to effective monitoring and treatment (5) . Patients with LVV can develop new vascular lesions during periods of apparent sustained clinical remission and with normal inflammation marker levels; temporal artery biopsies performed during clinical remission can demonstrate ongoing active vasculitis (6, 7) . Angiography is often recommended to complement clinical assessment; however, there are no guidelines for using imaging to assess LVV, and angiography may not be adequately sensitive to detect vascular inflammation prior to the onset of vessel wall damage (8) . FDG-PETcan detect metabolic activity from leukocytes infiltrating the walls of large arteries and may therefore be more sensitive than angiography to monitor vascular inflammation in LVV (9) .
While several studies have examined the potential of molecular imaging in LVV, the role of FDG-PET in detecting vascular inflammation, monitoring disease activity over time, and predicting clinical outcomes remains unclear. Most studies suggest that FDG-PET can detect vascular inflammation in LVV; however, these studies are mostly retrospective and involve healthy subjects or patients with cancer as comparators rather than patients with other conditions that clinically resemble LVV (10) (11) (12) (13) (14) (15) (16) (17) . The performance characteristics of FDG-PET in LVV should be determined against an appropriate comparator population for whom the test would be clinically indicated to rule out vasculitis. Additionally, most studies of FDG-PET in LVV have focused on the time of initial diagnosis, and the utility of FDG-PET to monitor disease activity or predict relapse is uncertain due to limited imagingbased assessments at later time points in the disease.
The objective of this study was to assess the role of FDG-PET as an imaging biomarker in a prospective, longitudinal cohort of patients with LVV and in a composite comparator group consisting mainly of patients with diseases that mimic LVV.
PATIENTS AND METHODS
Study population. Patients age ≥5 years were recruited into a prospective, observational cohort at the National Institutes of Health (NIH) in Bethesda, MD (ClinicalTrials.gov identifier: NCT02257866). All patients with LVV fulfilled the American College of Rheumatology (ACR) 1990 criteria for the classification of TAK (18) or the modified ACR 1990 criteria for the classification of GCA (19, 20) . Patients with LVV were enrolled at various stages during the disease, but initial imaging studies were preferentially performed during periods of clinically active disease or when taking <10 mg/day prednisone during clinical remission.
A composite disease comparator group was studied, consisting of patients with hyperlipidemia, patients referred to the NIH for possible LVV who were subsequently diagnosed as having a different condition (disease mimicking LVV), and healthy subjects. The hyperlipidemia group was recruited from a parallel study (ClinicalTrials.gov identifier: NCT01212900) as part of a larger investigation of atherosclerosis imaging related to statin treatment (21) . Patients with hyperlipidemia were age >55 years and required therapy with a statin. This group was chosen because atherosclerosis is a known radiographic mimic of LVV. Patients referred to the NIH for possible LVV who were determined to have another form of systemic inflammatory disease (e.g., polyarteritis nodosa) or a noninflammatory vasculopathy (e.g., fibromuscular dysplasia) were included as having disease mimicking LVV. This group underwent repeat clinical assessment at 6 months to ensure diagnostic accuracy. A group of healthy adult subjects was recruited across the age spectrum of TAK and GCA to serve as additional comparators.
Clinical assessment and definitions of disease activity. All patients were clinically evaluated and imaged at the NIH Clinical Center, and patients with LVV underwent repeat imaging studies and clinical assessments at 6-month intervals. Outside physician records were obtained throughout the study period and reviewed. All clinical assessments were performed by the investigative study team within 24 hours prior to imaging assessment. Physician-determined disease activity status was based upon clinical history, physical examination, and laboratory assessments and was recorded prior to conducting imaging studies. Active disease was defined as the presence at the time of assessment of any clinical disease feature directly attributed to vasculitis. Chronic fatigue or elevated acutephase reactant levels in the absence of clinical symptoms were not considered evidence of active disease. Remission was defined as the absence of any clinical symptoms directly attributable to vasculitis. A disease relapse was defined as a recurrence of clinical disease activity after a period of remission necessitating an increase in prednisone dose of ≥10 mg/day and/or addition of a glucocorticoid-sparing therapy. Relapse was determined by the investigative study team while blinded with regard to imaging findings. No clinical care or treatment decisions were made by the investigative team.
FDG-PET imaging protocol. PET studies were performed at each study visit. Subject preparation included instructions to consume a carbohydrate-sparse meal on the day before imaging and to fast on the day of imaging. Patients age ≥18 years underwent FDG-PET-computed tomography (CT) of the torso. At 2 hours of uptake time, image acquisition commenced with a Siemens Biograph mCT (Siemens Medical Solutions). Image reconstruction employed CT attenuation correction and iterative reconstruction (24 iterations, 3 subsets, 256 matrix, 1.29 zoom, slice thickness 1.5 mm, time-of-flight, point spread function correction, no postreconstruction filtering). To minimize radiation exposure, patients age <18 years underwent whole-body FDG-PET-magnetic resonance imaging (MRI) with a Siemens Biograph mMR (Siemens Medical Solutions). PET-MRI reconstruction employed MRI-based attenuation correction and iterative reconstruction (172 matrix, 1.29 zoom, slice thickness 2.03 mm, point spread function correction, 4.0 Gaussian postreconstruction filtering). Adult patients received a fixed dose of 18 F-FDG (10 mCi), and pediatric patients received a weightbased dose (0.1 mCi/kg).
Nuclear medicine physician interpretation of FDG-PET findings. Two nuclear medicine physicians (MAA and ACC) interpreted all PET scans included in this study while blinded with regard to clinical data and to each other's assessment. PET interpretation determined whether the findings were consistent with active or inactive vasculitis based upon assessment of vascular FDG uptake. Discrepancies between the readers were adjudicated ≥2 weeks after the initial assessment. During adjudication, the readers were blinded with regard to results from the initial assessment, and the final impression of imaging activity was determined by consensus review.
Qualitative assessment of FDG uptake in arterial territories and creation of the PET Vascular Activity Score (PETVAS). A single nuclear medicine physician (MAA) performed qualitative assessment of FDG uptake in 4 segments of the aorta (ascending, arch, descending thoracic, and abdominal) and in 11 branch arteries (innominate, carotids, subclavians, axillaries, iliacs, and femorals). The degree of arterial uptake was visually assessed relative to liver uptake as: 0 = no uptake; 1 = less than liver uptake; 2 = same as liver uptake; 3 = greater than liver uptake (12, 22) . Only FDG-PET-CT scans were considered for qualitative review. To assess the qualitative burden of arterial FDG uptake across multiple arterial regions, a summary score (hereafter termed the PETVAS) was created by adding the qualitative scores in specific arterial territories where the mean qualitative scores were significantly higher in LVV patients than in comparators (for calculation of the PETVAS, see Supplementary Table 1 Characteristics of FDG-PET interpretation (sensitivity, specificity, receiver operating characteristic [ROC] curve) were calculated. Overall image interpretation, rather than qualitative assessment, was considered the gold standard for determining PET scan activity. Interobserver agreement of PET interpretation was assessed by the kappa statistic. Mixed effects logistic regression, adjusting for within-patient correlated data as a random effect, was performed to study the associations between nuclear medicine physician interpretation of active vasculitis on the PET scan (outcome measure) and the following predictor variables: clinical disease activity status, disease duration since the time of initial symptom onset, body mass index (BMI), form of LVV, current use of glucocorticoid-sparing therapy, age, daily prednisone dose, sex, erythrocyte sedimentation rate (ESR), and serum levels of fibrinogen, endothelin 1, and C-reactive protein (CRP). Only variables with P values less than 0.2 in univariable analyses were included in the multivariable model.
Correlation between the PETVAS and selected clinical variables in patients with LVV stratified by clinical disease activity status was assessed using Spearman's correlation coefficient. For the correlation analyses, repeated measures were averaged over successive visits if there was no change in clinical status. Differences between distributions of continuous data were compared using Student's 2-tailed t-test or the MannWhitney U test for pairwise comparisons and one-way analysis of variance or the Kruskal-Wallis test with post hoc testing for comparisons across multiple groups, as appropriate. Fisher's exact test was used to assess differences in categorical data. P values less than 0.05 were considered significant.
Ethics and informed consent. All patients provided written informed consent. An institutional review board and radiation safety committee at the NIH approved the research.
RESULTS
Characteristics of the study population. From September 2014 through February 2017, a total of 115 participants were recruited into the study. There were 56 patients with LVV (30 with GCA and 26 with TAK) and 59 comparator subjects (35 with hyperlipidemia, 17 with disease mimicking LVV, and 7 healthy controls). A total of 170 FDG-PET scans were performed, including 111 scans in patients with LVV and 59 scans in the comparator group. Among patients with LVV, 35 (63%) underwent at least 1 follow-up PET scan over a mean AE SD follow-up period of 6.3 AE 6.7 months. Demographic characteristics of the study participants are presented in Table 1 . Additional clinical features of the patients with LVV stratified by vasculitis type and disease activity status are presented in Supplementary features of disease activity are listed in Supplementary  Table 3 . Diagnoses in the group with disease mimicking LVV are provided in Supplementary Table 4 . Five children with TAK and 3 children with conditions mimicking LVV were included in this study.
Performance characteristics of FDG-PET. There was excellent agreement between the 2 independent nuclear medicine physicians regarding whether PET scan findings demonstrated active vasculitis (j = 0.84, 95% confidence interval [95% CI] 0.75, 0.94). Seventy-five of 111 scans (68%) performed in patients with LVV were interpreted as consistent with active vasculitis (Table 1) . Fewer scans performed in the comparators were interpreted as consistent with active vasculitis (10 of 59 scans [17%]).
Results from the adjudicated interpretation of FDG-PET scans are displayed in Table 2 . The proportions of subjects who had a PET scan interpreted as active vasculitis were as follows: 34 of 40 with clinically active LVV, 41 of 71 with LVV in remission, and 10 of 59 comparators. FDG-PET had sensitivity of 85% (95% CI 69, 94) and specificity of 83% (95% CI 71, 91) to distinguish between patients with clinically active LVV and comparator subjects. FDG-PET had specificity of 42% (95% CI 31, 55) Clinical predictors of FDG-PET activity. Regression modeling was used to determine the clinical variables associated with interpretation of PET scan activity. In a multivariable model, clinically active disease, shorter disease duration, lower BMI, and lower amounts of daily prednisone use were independently associated with increased odds of the PET scan being interpreted as active vasculitis (Table 3) . Acute-phase reactant levels, age, sex, type of vasculitis (GCA versus TAK), and use of glucocorticoid-sparing therapies were not significantly associated with physician interpretation of PET scan activity. Effect estimates for type of vasculitis and prednisone use varied considerably between the univariable and multivariable models, indicating that the association between these variables and PET scan activity was strongly influenced by other predictor variables within the multivariable model.
Qualitative assessment of global arterial FDG uptake (PETVAS). Distribution of arterial FDG uptake on a qualitative scale of 0-3, with higher scores indicating increased uptake, is shown in Figure 1A . There was significantly increased FDG uptake in the ascending aorta, aortic arch, descending thoracic aorta, abdominal aorta, and carotid and subclavian arteries for patients with LVV versus comparators (P < 0.001). There were no differences in arterial FDG uptake in the axillary, The mean PETVAS was significantly higher in scans visually interpreted as active vasculitis than in those visually interpreted as inactive vasculitis (21.5 versus 12.2; P < 0.0001), indicating that a global pattern of FDG uptake tended to result in an interpretation of active vasculitis ( Figure 1B) . The PETVAS was significantly higher in patients with GCA or TAK who had visual evidence of active vasculitis on PET than in subjects in any of the specific comparator groups (Figure 1C) . The PETVAS was significantly higher in both GCA and TAK during periods of clinically determined Lines outside the boxes represent the 10th and 90th percentiles. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001, by Student's 2-tailed t-test (A and B) or one-way analysis of variance with Tukey's post hoc test for multiple comparisons (C and D). Ao = aorta; NS = not significant. active disease than during periods of clinical remission ( Figure 1D ). Among patients considered by the clinical investigator to have LVV in clinical remission, a higher PETVAS was observed in GCA than in TAK. An ROC curve indicated fair performance characteristics (area under the curve = 0.72) of the PETVAS to distinguish between clinically active LVV and remission ( Figure 1E) , with a cut point of ≥20 yielding a sensitivity of 68% (95% CI 50, 83) and a specificity of 71% (95% CI 58, 82).
PETVAS associations during active disease and clinical remission. To test whether factors associated with the degree of arterial FDG uptake differ in patients during periods of active clinical disease versus clinical remission, associations between the PETVAS and specific clinical features were studied in patients with LVV stratified by clinical disease activity status. Among patients with clinically active disease (Table 4) , there were moderate positive correlations between specific acute-phase reactants (ESR, CRP, fibrinogen) and the PETVAS (r = 0.36-0.52). Amount of daily prednisone use was inversely associated with arterial FDG uptake, while age and BMI were not associated with FDG uptake. A different pattern of associations was observed in patients with LVV during clinical remission; age was positively and BMI negatively associated with the PETVAS, while acute-phase reactant levels and daily prednisone use were not significantly associated with the PETVAS.
Value of FDG-PET for predicting clinical relapse in LVV. The value of PET scan findings for predicting clinical events was studied. Thirty-nine patients with LVV who underwent an FDG-PET-CT scan during a period of clinical remission and had at least 3 months of clinical followup were selected within the cohort. Eight of these patients experienced a clinical relapse over a median follow-up period of 15 months. Based on a PETVAS threshold of 20, which optimally distinguished patients with clinically active LVV from those with LVV in clinical remission ( Figure 1E ), patients were categorized during clinical remission as having a high amount of arterial FDG uptake (PETVAS ≥20) or a lower amount of arterial FDG uptake (PETVAS <20). Significantly more patients with a PETVAS of ≥20 experienced future clinical relapse compared to patients with a PETVAS of <20 (55% versus 11%; P = 0.03) (Figure 2A) . Clinical characteristics of these patients are shown in Supplementary  Table 6 , http://onlinelibrary.wiley.com/doi/10.1002/art. 40379/abstract.
The mean daily prednisone dose in both groups was ≤5 mg at the time of imaging. Patients with a PETVAS of ≥20 were more likely to have GCA than TAK, had significantly shorter disease duration, and were less likely to be taking glucocorticoid-sparing therapies compared to patients with a PETVAS of <20 (P < 0.05). Representative PET scan images from 2 patients with a high PETVAS during clinical remission and who subsequently experienced a clinical relapse are shown in Figures 2B and C. A temporal artery biopsy was performed in 1 patient during a period of apparent clinical remission when the FDG-PET scan findings were interpreted as active vasculitis (a PETVAS of 27). The biopsy was diagnostic for active vasculitis, revealing transmural inflammation and giant cells ( Figure 2D ).
DISCUSSION
This study demonstrates that FDG-PET provides information about vascular inflammation that is at times contradictory to clinical assessment in LVV. While most patients with clinically active vasculitis had FDG-PET scan findings that demonstrate concordant vascular inflammation, the majority of patients with LVV in clinical remission also had FDG-PET scan findings interpreted by independent nuclear medicine physicians as active vasculitis. In the absence of contemporaneous histologic samples, it is unclear whether increased metabolic activity in the vascular wall detected in patients with LVV during clinical remission represents subclinical vasculitis (23), a secondary process such as vascular remodeling, hypoxia (24), atherosclerosis (2), or a combination of these factors. While FDG uptake correlates with histologic macrophage density in animal models of atherosclerosis (25) , altered metabolism in endothelial or smooth muscle cells secondary to vascular remodeling rather than active inflammation could also contribute to PET scan activity observed within the arterial wall in patients with LVV during clinical remission. F-FDG uptake (the PETVAS) calculated in patients with LVV during clinical remission predicts future clinical relapse. Patients with a high PETVAS (≥20) were significantly more likely to have disease relapse than were patients with a lower PETVAS (<20) (6 of 11 [55%] versus 3 of 28 [11%]; P = 0.03). B, Left, PET-computed tomography (CT) obtained in a patient with GCA during clinical remission (disease duration 3 years, taking 2.5 mg prednisone every other day) shows substantial FDG uptake throughout the aorta and branch vessels (arrows). Right, The patient experienced disease relapse (mesenteric ischemia, fatigue, newly elevated acute-phase reactant levels) 1 month after the baseline scan and was treated with methotrexate and tapered glucocorticoids with improvement of arterial FDG uptake (arrows). C, A patient with GCA in apparent clinical remission (disease duration 1 year, taking 7 mg prednisone every day) had severe arterial FDG uptake in the aorta and branch vessels (arrows) with normal inflammation marker levels. Upon further reduction of prednisone to 3 mg/day during the subsequent 6 months, the patient experienced clinical relapse of disease (polymyalgia rheumatica, fatigue, elevated acute-phase reactant levels) necessitating additional therapy. D, A temporal artery biopsy performed in a patient with GCA during clinical remission with FDG-PET-CT findings suggestive of active vasculitis demonstrated transmural inflammation with giant cells (inset). Original magnification 940. See Figure 1 for other definitions.
Despite the lack of histologic confirmation, results from this study strongly suggest that subclinical vascular inflammation is likely a major contributor to the varying degree of arterial FDG uptake observed during clinical remission. Patients with LVV who had a high global burden of arterial FDG uptake during clinical remission were at risk of clinical relapse over a median 15 months of follow-up time. Histologic evidence of vasculitis was demonstrated in a temporal artery biopsy sample from a patient in apparent clinical remission with a PET scan indicating active vasculitis ( Figure 2D ). The amount of vascular FDG uptake detected during clinical remission was reduced over time in response to treatment (e.g., Figure 2B ). These findings raise important questions about how to define disease activity and remission in LVV, and they support findings of prior autopsy studies that demonstrate ongoing vascular inflammation in patients with LVV who otherwise had disease in clinical remission at the time of death (26, 27) .
Several studies have shown that FDG-PET can detect vascular inflammation in LVV. A recent metaanalysis of 8 studies examining the performance of FDG-PET for detecting vasculitis in LVV (10, (12) (13) (14) (15) (16) (17) 22) showed a pooled sensitivity of 76% (95% CI 69, 82) and specificity of 93% (95% CI 89, 96) (28) . These findings differ slightly from the performance characteristics of FDG-PET in the present study, which distinguished patients with active LVV from comparators with sensitivity of 85% and specificity of 83%. Our study differs from others in some techniques. To be consistent with the recommended procedure for atherosclerosis imaging (29) , FDG-PET-CT images were obtained in the current study at a delayed uptake time of 2 hours compared to a 1-hour uptake time used in all previous studies. Delay in the time interval from injection of FDG to image acquisition can increase the sensitivity for detecting FDG uptake in the arterial wall by allowing more time for distribution of FDG into tissue with concomitant elimination from the blood pool. Selection of a comparator population from those with diseases that resemble LVV rather than from healthy controls and patients with cancer, as done in previous studies, likely contributed to the lower specificity observed in the current study. Notably, 17% of subjects in the comparator group had FDG-PET scan findings interpreted as active vasculitis, emphasizing that a diagnosis of LVV should not be made solely based on FDG-PET findings.
FDG-PET performed poorly as a biomarker of disease activity in LVV against a clinical reference standard, as most patients with disease in clinical remission had PET scan findings interpreted as ongoing vascular inflammation. There are minimal data on FDG-PET findings during clinical remission in GCA, with 1 study noting increased arterial uptake in a sizable portion of patients during clinical remission (30) . Several studies suggest a stronger correlation between FDG uptake and clinical disease activity in TAK compared to GCA (9) . However, in a recent meta-analysis, vascular FDG uptake did not consistently correlate with disease activity in TAK, and there was considerable heterogeneity in 7 studies (31) (32) (33) (34) (35) (36) (37) , with a pooled sensitivity of 86% (95% CI 78, 93) and specificity of 73% (95% CI 63, 81) (38) . In the present study, 48% of PET scans performed in patients with TAK and 62% of PET scans performed in patients with GCA during clinical remission were interpreted as active vasculitis (see Supplementary Table 2 , http://onlinelibrary.wiley.com/doi/10. 1002/art.40379/abstract), and the global burden of arterial uptake during clinical remission was significantly higher in patients with GCA than in patients with TAK ( Figure 1D ). These findings corroborate prior reports that PET scan activity does not correlate with clinical disease assessment in LVV, and they highlight a greater discordance between clinical and imaging assessment in patients with GCA compared to patients with TAK.
Associations between clinical features and arterial FDG uptake suggest that additional factors beyond subclinical vasculitis also contribute to vascular FDG uptake during clinical remission in LVV. In studies of atherosclerosis, age and BMI are positively associated with arterial FDG uptake; however, the results are not uniform among those studies (39) . In the present study, age was positively but only modestly correlated with the degree of vascular uptake in patients with LVV during clinical remission and not during active disease. A greater burden of arterial uptake during clinical remission was observed in patients with GCA, who are by disease definition older, compared to patients with TAK. These findings suggest that atherosclerosis contributes in part to vascular FDG uptake in LVV during clinical remission.
Disease duration was significantly shorter in patients with GCA than in patients with TAK in this study, which may further explain the differences observed in arterial uptake between these diseases during remission. In multivariable regression models, disease duration, and not age or type of vasculitis, was significantly and inversely associated with PET scan activity. Patients with GCA had a higher burden of vascular PET scan activity during remission compared to patients with TAK, potentially because patients with GCA in remission were assessed closer to the time of initial diagnosis than were patients with TAK. Furthermore, the inverse association between disease duration and vascular uptake in clinical 446 GRAYSON ET AL remission suggests that the burden of vascular inflammation decreases over time in LVV, an unexpected finding if vascular uptake during remission was primarily driven by atherosclerosis or accrued vascular damage.
Results from previous studies on the value of FDG-PET scan for predicting clinical relapse have been inconclusive. One previous study failed to demonstrate predictive value of FDG-PET in 35 patients with GCA; however, all patients in that study were studied early in the course of disease (3 and 6 months after diagnosis) and were receiving moderate doses of glucocorticoids at the time of imaging, which could have dampened the predictive value of PET (30) given that increasing prednisone dose is negatively associated with activity on PET scan (Table 3) . A recent study demonstrated prognostic value of FDG-PET at the time of diagnosis in patients imaged before starting glucocorticoid therapy (40) . In the current study, the burden of arterial uptake during clinical remission predicted relapse in patients who were assessed on average several years into the course of disease while taking minimal doses of glucocorticoids. While a PETVAS threshold of 20 was useful for predicting clinical relapse, a threshold score to define PET scan activity was not proposed in this study. A substantial number of PET scans with PETVAS of <20 were interpreted by independent readers as demonstrating active vasculitis, particularly in scans where there was intense FDG uptake confined to focal arterial territories.
This study has some important potential limitations to consider. This was a single-center study that was subject to assessment bias from the participating investigators. However, interrater agreement for independent and blinded PET scan interpretation was excellent. Physician interpretation and qualitative metrics rather than semiquantitative values (e.g., standardized uptake values) were used to assess arterial FDG uptake. The standardization of semiquantitative values to study vascular inflammation is of recent interest (29) and should be the subject of future investigations (9) . Patients with LVV could be enrolled at any time in the disease course, limiting the ability to assess performance characteristics of FDG-PET at the time of diagnosis. We did not assess whether FDG-PET findings predicted progression of disease on angiography.
This study has several important strengths. The study was prospective, larger than previous studies, contained patients with GCA and those with TAK (which enabled comparative assessment across different forms of vasculitis), included children and a composite group of comparator subjects with vasculopathy, and introduced a new qualitative summary score of arterial FDG uptake (the PETVAS). Unlike previous studies that have created a summary score based on qualitative FDG uptake in specific arterial territories to represent global burden of inflammation (30) , the arterial territories included in the PETVAS were determined by a data-driven approach comparing differences in qualitative scores between patients with LVV and a relevant comparator group.
In conclusion, findings from this study demonstrate that advanced imaging techniques provide information about disease activity that is complementary to, and distinct from, clinical assessment. This study provides novel, prospective evidence about the potential value of FDG-PET scans in patients with LVV who are assessed months to years in the course of disease. While serial monitoring of patients with FDG-PET may identify vascular abnormalities in patients with LVV otherwise in apparent clinical remission, use of FDG-PET to monitor vascular inflammation in routine clinical practice is not currently advisable. The value of FDG-PET later in the course of disease needs to be tested and validated in additional independent cohorts of patients with LVV who are monitored over longer periods of observation, ideally starting at the time of initial diagnosis, to determine whether PET abnormalities during clinical remission are associated with poor long-term clinical outcomes, including vascular progression of disease. However, this study provides preliminary evidence that FDG-PET performed in patients with LVV during established clinical remission can identify subsets of patients at risk of clinical relapse.
This study also demonstrates that simple metrics of arterial FDG uptake are useful for quantifying the burden of vascular abnormalities on PET scans. Whether such assessments could function as a useful outcome measure to monitor vascular inflammation should be tested in clinical trials. Previous histopathologic studies demonstrated a disconnect between clinical assessment and vascular disease activity in LVV; this study provides additional imaging-based data about how to define disease activity in these complex conditions.
